Outcome of Board Meeting
The following items were considered and approved: 1.Audited Financial Results of the Company for the year ended March 31, 2017; 2.Dividend recommendation of Rs 10/- per equity share of Rs 5/- each for the year ended March 31, 2017; 3.Convening of the AGM of the Company on Friday, July 28, 2017; 4.Closure of the Register of Members and Share Transfer books from Friday, July 21, 2017 to Friday, July 28, 2017, both days inclusive, for determining... Board to consider Final Dividend
Novartis India Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled to be held on May 23, 2017, inter alia, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2017, and to recommend final dividend, if any. Board Meeting On May 23, 2017
In continuation to our letter dated March 31, 2017, please find enclosed copies of notice that was published in the Financial Express and Navshakti on May 9, 2017. Torrent Pharma acquires two women healthcare brands from Novartis
Ahmedabad based Rs 6,600 croreTorrent Pharma has completed the acquisition of women healthcare brands Regestrone and Pregachieve for India from Swiss pharma major Novartis AG. While the company did not disclose the deal size, it is estimated to be close to Rs 500 crore. Torrent was in talks to acquire these brands since the last few months and had entered into a pact with Novartis last month to acquire the two brands. Both the brands are prescribed by gynaecologists for management of abnormal uterine bleeding, peri and post menopausal symptoms and infertility. Torrent said in a release here that women healthcare is an important therapy area for the company and it intends to focus on it in the future. "With acquisition of key brands of Elder like Shelcal and Deviry, impetus on this therapy area has also increased. Regestrone and Pregachieve will further fortify the Hormone Segment. The use of Hormones amongst the Gynaecologists is on an increase because of lifestyle changes," the... Updates
Disclosure under Regulation 30(1) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 US FDA approves Novartis' leukemia treatment
The U.S. Food and Drug Administration approved Novartis AG's Rydapt as an initial treatment for acute myeloid leukemia (AML) as well as certain other blood disorders, the agency said on Friday.... Updates
Please find enclosed copies of notice that was published on April 18, 2017 in the Financial Express and Navshakti for the attention of equity shareholders of the Company in respect of transfer of equity shares to Investor Education and Protection Fund (IEPF) Suspense Account. Compliance Certificate For The Period Ended 31St March 2017
Pursuant to Regulation 7(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, we hereby confirm that the activities in relation to both physical and electronic share transfer facility for the period from October 1, 2016 to March 31, 2017 are maintained with the Company's Registrar and Share Transfer Agent, Link Intime India Private Limited, having its registered office at C 101, 247 Park, LBS Marg, Vikhroli West, Mumbai... Shareholding for the Period Ended March 31, 2017
Novartis India Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2017. For more details, kindly Click here